Pharmaceuticals
July 13, 2020
David Feifel, David Dadiomov, Kelly C. Lee
The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to...
Neurochemistry International
July 8, 2020
A. Camargo, A. P. Dalmagro, Julia M. Rosa et al.
Augmentative treatment is considered the best second-option when a first-choice drug has partial limitations, particularly by allowing antidepressant dose reduction. Considering that ketamine has significant knock-on effects, this study investigated the effects of single coadministration with subthreshold doses of ketamine plus guanosine in a corticosterone (CORT)-induced animal model of...
July 1, 2020
Nathaniel A. Shanok, Carol Reive, Krystal D. Mize et al.
Abstract. Mindfulness meditation interventions (MMIs) are formal training programs which utilize mindfulness techniques to improve attentional control and reduce stress and anxiety. Past investigat...
Journal of Nursing Science Update
June 30, 2020
Maria Julieta Esperanca Naibili, Iman Permana
Depression is a common mental disorder that is leading cause of disability in the world by 2020 and a major contributor to overall global disease burden. Globally, more than 300 million people of all ages suffer from depression and more women. Depression can affect aspects of life including psychological, physical, and social. MBCT teaches patients through the mind, feelings, and body...
Translational Psychiatry
June 26, 2020
Paulo R Shiroma, Paul Thuras, Joseph Wels et al.
112 citations
The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine. However, consensus guideline stated the lack of evidence to support frequent ketamine administration. We compared the efficacy and safety of single vs. six repeated ketamine using midazolam as active placebo. Subjects...
General Psychiatry
June 18, 2020
Xiao-Mei Li, Zhan-Ming Shi, Hua Hu et al.
13 citations
Background The use of ketamine in electroconvulsive therapy (ECT) has been examined in the treatment of major depressive disorder (MDD); however, there has been no systematic review and meta-analysis of related randomised controlled trials (RCTs).Aim To examine the efficacy and safety of ketamine augmentation of ECT in MDD treatment.Methods Two reviewers searched Chinese (China National...
JMIR Mental Health
June 17, 2020
Christo El Morr, Paul Ritvo, F. Ahmad et al.
Background A student mental health crisis is increasingly acknowledged and will only intensify with the COVID-19 crisis. Given accessibility of methods with demonstrated efficacy in reducing depression and anxiety (eg, mindfulness meditation and cognitive behavioral therapy [CBT]) and limitations imposed by geographic obstructions and localized expertise, web-based alternatives have become...
Molecular Brain
June 16, 2020
L. Aleksandrova, Y. Wang, A. Phillips
87 citations
Accumulating evidence implicates dysregulation of hippocampal synaptic plasticity in the pathophysiology of depression. However, the effects of ketamine on synaptic plasticity and their contribution to its mechanism of action as an antidepressant, are still unclear. We investigated ketamine’s effects on in vivo dorsal hippocampal (dHPC) synaptic plasticity and their role in mediating aspects of...
International Journal of Geriatric Psychiatry
June 11, 2020
Elena Dikaios, Sophia Escobar, Marouane Nassim et al.
Mindfulness‐based cognitive therapy (MBCT) is a novel treatment for depression. Our published randomized controlled trial shows that MBCT improves symptoms of late‐life depression (LLD) and anxiety (LLA). We now examine whether continuation sessions of MBCT (MBCT‐C) can prevent LLD/LLA symptom recurrence.
International Review of Psychiatry
June 5, 2020
Ben Carter, Rebecca Strawbridge, Muhammad Ishrat Husain et al.
45 citations
Most interventions for treatment-resistant depression (TRD) are added as augmenters. We aimed to determine the relative effectiveness of augmentation treatments for TRD. This systematic review and network meta-analysis (NMA) sought all randomized trials of pharmacological and psychological augmentation interventions for adults meeting the most common clinical criteria for TRD. The NMA compared...
Open Repository of the University of Porto (University of Porto)
June 5, 2020
Rui Pedro Leal Andrade
Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed by indigenous cultures for millenia, Psilocybin, in the 1960s, was marketed in many countries under the trade name Indocybin, and, before its eventual ban, was safely used as an adjunct to psychotherapy in the treatment of depression and anxiety....
Frontiers in Psychiatry
June 3, 2020
Alina Wilkowska, Łukasz P. Szałach, Jakub Słupski et al.
9 citations
There is a growing evidence for the rapid and robust antidepressive effect of ketamine in unipolar and bipolar treatment resistant depression although evidence for the risk of affective switch is still limited. This case presents bipolar I disorder patient with treatment resistant depressive episode experiencing a switch to manic episode with mixed features shortly after receiving eight...
ACS Chemical Neuroscience
June 3, 2020
Paola Rodrı Guez, Jessika Urbanavicius, José Pedro Prieto et al.
44 citations
Anecdotal reports and open-label case studies in humans indicated that the psychedelic alkaloid ibogaine exerts profound antiaddictive effects. Ample preclinical evidence demonstrated the efficacy of ibogaine, and its main metabolite, noribogaine, in substance-use-disorder rodent models. In contrast to addiction research, depression-relevant effects of ibogaine or noribogaine in rodents have...
BMC Psychiatry
June 2, 2020
J. Phillips, N. Jaworska, Elizabeth Kamler et al.
22 citations
Background Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidepressant treatment strategies in large randomized trials. This study protocol describes an ongoing...
Mindfulness
June 1, 2020
Kristina Sundquist, Karolina Palmér, Ashfaque A. Memon et al.
Abstract Objectives Identification of biological markers that can guide treatment selection is considered to be a viable solution for personalized treatment for patients with psychiatric disorders. This study investigated whether macrophage migration inhibitory factor (MIF) levels at baseline were associated with mindfulness-based group therapy or cognitive behavioral therapy response in...
Trends in Psychiatry and Psychotherapy
June 1, 2020
Aliakbar Foroughi, Kheirollah Sadeghi, A. Parvizifard et al.
Introduction Depression is one of the most important psychiatric disorders, and the rate of recurrence is high. The heavy cost burden of depression is probably due to treatment-resistant depression. The purpose of this study was to determine the effectiveness of mindfulness-based cognitive therapy (MBCT) in patients with treatment-resistant depression (TRD). Method The present study was a...
Mindfulness
June 1, 2020
Paweł Holas, Izabela Krejtz, Katarzyna Wisiecka et al.
Abstract Objectives Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment to prevent relapse in individuals with recurrent major depressive disorder (MDD). It is not clear if MBCT is an effective therapy for current depression, and it is not clear what mechanisms are responsible for the effectiveness of MBCT. Theoretically, MBCT is believed to modify the processing of...
Journal of Psychedelic Studies
June 1, 2020
Mitch Earleywine, Joseph A. de Leo
12 citations
Abstract Despite the popular support for psychedelics as aids for depression, academics and the public frequently overestimate the efficacy of available medications and psychotherapies. Metaanalyses reveal that antidepressant medications alone help only one in four patients and rarely surpass credible placebos. Their effects, though statistically significant, might not impress depressed...
Frontiers in Integrative Neuroscience
May 28, 2020
Anna Xu, Chloe S. Zimmerman, Sara W. Lazar et al.
Objective: Tai chi (TC), a contemplative practice combining slow movements and deep breathing, has been shown to be clinically effective in alleviating depressive symptoms. Feelings of fatigue or low vitality often accompany major depressive disorder (MDD) though they are commonly overlooked and not well understood neurologically. By using resting state functional connectivity (rs-FC) using the...
Sleep
May 27, 2020
T Shapiro, B Messman, Danica C. Slavish et al.
Abstract: Introduction: Nurses report a higher prevalence of posttraumatic stress disorder (PTSD) than the general population, and approximately 18% of nurses report having depression. Nightmares are a common symptom of PTSD, and both nightmares and PTSD are correlated with depression. Nightmares may represent a possible clinical target for improving outcomes in both disorders. This study...